Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 440

The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.

Programmed death ligand 1 expression in hepatocellular carcinoma: Relationship With clinical and pathological features

Open access
Calderaro, Julien, Rousseau, Benoît, Amaddeo, Giuliana, Mercey, Marion, Charpy, Cécile, Costentin, Charlotte, Luciani, Alain, Zafrani, Elie‐Serge, Laurent, Alexis, Azoulay, Daniel, Lafdil, Fouad, Pawlotsky, Jean‐Michel·2016·Hepatology

Abstract

The prognosis of hepatocellular carcinoma (HCC) remains poor, with only one third of patients eligible for curative treatments and very limited survival benefits with the use of sorafenib, the current standard of care for advanced disease. Recently, agents targeting the programmed death ligand 1 (PD‐L1)/programmed death receptor 1 (PD‐1) immune checkpoint were shown to display impressive antitumor activity in various solid or hematological malignancies, including HCC. PD‐L1 immunohistochemical expression is thought to represent a biomarker predictive of drug sensitivity. Here, we investigated PD‐L1 expression in a series of 217 HCCs and correlated our results with clinical and histological features and immunohistochemical markers (PD‐1, cytokeratin 19, glutamine synthetase, and β‐catenin expression). PD‐L1 expression by neoplastic cells was significantly associated with common markers of tumor aggressiveness (high serum alpha‐fetoprotein levels, P = 0.038; satellite nodules, P < 0.001; macrovascular invasion, P < 0.001; microvascular invasion, P < 0.001; poor differentiation, P < 0.001) and with the progenitor subtype of HCC (cytokeratin 19 expression, P = 0.031). High PD‐L1 expression by inflammatory cells from the tumor microenvironment also correlated with high serum alpha‐fetoprotein levels (P < 0.001), macrovascular invasion (P = 0.001), poor differentiation (P = 0.001), high PD‐1 expression (P < 0.001), and the so‐called lymphoepithelioma‐like histological subtype of HCC (P = 0.003). Conclusion: PD‐L1 expression by either neoplastic or intratumoral inflammatory cells is related to tumor aggressiveness and suggests that the response to treatments targeting the PD‐L1/PD‐1 immune checkpoint could be restricted to particular HCC variants; thus, enrichment of these tumor subtypes in future clinical trials should be considered. (H epatology 2016;64:2038‐2046)

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/hep.28710

Cites

34 of 34 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 34 references

Cited by

See all 440

Metadata

Authors
Calderaro, J., Rousseau, B., Amaddeo, G., Mercey, M., Charpy, C., Costentin, C., Luciani, A., Zafrani, E., Laurent, A., Azoulay, D., Lafdil, F., & Pawlotsky, J.
Venue
Hepatology
Published
2016-08-09
Volume
64
Issue
6
Pages
2038-2046
ISSN
  • 0270-9139 (ISSN-L)
  • 1527-3350
OpenAlex
W2499029168
Cited by
440
References
34
FWCI
24.08
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Programmed death ligand 1 expression in hepatocellular carcinoma: Relationship With clinical and pathological features. https://app.cochat.ai/papers/10.1002/hep.28710
The paper
Calderaro, J., Rousseau, B., Amaddeo, G., Mercey, M., Charpy, C., Costentin, C., Luciani, A., Zafrani, E., Laurent, A., Azoulay, D., Lafdil, F., & Pawlotsky, J. (2016). Programmed death ligand 1 expression in hepatocellular carcinoma: Relationship With clinical and pathological features. Hepatology. https://doi.org/10.1002/hep.28710

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.